Empowering the Veterinary Workforce by Broadening Educational Access
Veterinary technicians play a vital role in the veterinary field, carrying out important tasks such as assisting in surgeries, conducting diagnostic tests, and providing emergency care. To meet the increasing…
Gilead Shares New Efficacy, Safety, and Demographic Data from PURPOSE 2 Trial at HIV Research for Prevention Conference
Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor,…
Gilead to Showcase Antiviral Portfolio and HIV Innovations at IDWeek 2024
Gilead Sciences, Inc. has announced the presentation of new findings from its antiviral research and development programs at IDWeek 2024, scheduled for October 16-19. The presentations will include data from…
Results from Phase 3 TALAPRO-2 Trial Indicate TALZENNA and XTANDI Boost Overall Survival
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)…
FDA Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in adults…
Airsupra Reduces Risk of Severe Asthma Exacerbations in Phase III BATURA Trial
AstraZeneca’s Airsupra (albuterol/budesonide) has demonstrated promising outcomes in the BATURA Phase IIIb trial, achieving its primary endpoint by significantly and meaningfully reducing the risk of severe asthma exacerbations when used…
Most Children with SMA Treated with Evrysdi Achieve Motor Milestones, Two-Year Data Shows
Roche (SIX: RO, ROG; OTCQX: RHHBY) presented promising two-year findings from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, held from October 8-12, 2024. The study…
FDA Approves Roche’s Itovebi for Advanced Breast Cancer with PIK3CA Mutation
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib) for use in combination with palbociclib (Ibrance®) and fulvestrant to treat…
Merck to Present New Data on Vaccines and Infectious Disease at IDWeek 2024
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced plans to present new research at IDWeek 2024 in Los Angeles, CA, from October 16-19. The company…
Merck’s KEYTRUDA Achieves EFS Success in Perioperative Treatment for Head and Neck Cancer
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced today that its Phase 3 KEYNOTE-689 trial met the primary endpoint of event-free survival (EFS) for KEYTRUDA®…
FDA Approves COBENFY How Segal Trials are Transforming Schizophrenia Treatment
SSegal Trials is proud to have played a significant role in the FDA approval of COBENFY™ (xanomeline and trospium chloride), a pioneering first-in-class muscarinic agonist developed by Bristol Myers Squibb…
AHF Urges Wider Availability of Lenacapavir for Global HIV Treatment
The AIDS Healthcare Foundation (AHF) has expressed support for Gilead’s recent decision to expand the availability of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with…